Tag
This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.
This secondary analysis of the ARCHES trial demonstrates that enzalutamide plus ADT improves progression-free and overall survival in mHSPC patients across PSA levels, with undetectable PSA strongly predicting favorable outcomes.
The GROUQ-PCS 9 trial demonstrates that adding stereotactic body radiotherapy to standard androgen deprivation therapy and enzalutamide significantly prolongs radiographic progression-free survival in oligometastatic castration-resistant pr
The PEACE-3 trial demonstrates that adding radium-223 to enzalutamide significantly improves radiological progression-free survival and suggests an overall survival benefit in metastatic castration-resistant prostate cancer with bone metast
KEYNOTE-991 shows pembrolizumab does not improve progression-free or overall survival for mHSPC, and increases serious adverse events when added to enzalutamide and ADT.
Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant...